Akebia Therapeutics Inc.
AKBA
Market Cap$640.02M
Close$
$-2.12
180.9% downside
Current Fair Value
180.9% downsideOvervalued by 180.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $640.02 Million |
|---|---|
| Enterprise Value | $635.79 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.33 |
| Beta | 0.86 |
| Outstanding Shares | 218,699,008 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.72 |
|---|---|
| PEG | 0.2 |
| Price to Sales | - |
| Price to Book Ratio | -2.62 |
| Enterprise Value to Revenue | 4.02 |
| Enterprise Value to EBIT | -12.22 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.97 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler